[HTML][HTML] Masking MALT1: the paracaspase's potential for cancer therapy
D Vucic, VM Dixit - The Journal of experimental medicine, 2009 - ncbi.nlm.nih.gov
D Vucic, VM Dixit
The Journal of experimental medicine, 2009•ncbi.nlm.nih.govA key feature of aggressive B cell lymphomas is constitutive NF-κB activation, which requires
signals from the CARD11–BCL-10–MALT1 (CMB) complex. The unique enzymatic activity of
MALT1 degrades one of its binding partners, BCL-10, as well as the NF-κB inhibitor A20.
New data shows that targeting MALT1 protease activity may be a promising therapeutic
strategy for treating aggressive B cell lymphomas.
signals from the CARD11–BCL-10–MALT1 (CMB) complex. The unique enzymatic activity of
MALT1 degrades one of its binding partners, BCL-10, as well as the NF-κB inhibitor A20.
New data shows that targeting MALT1 protease activity may be a promising therapeutic
strategy for treating aggressive B cell lymphomas.
Abstract
A key feature of aggressive B cell lymphomas is constitutive NF-κB activation, which requires signals from the CARD11–BCL-10–MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the NF-κB inhibitor A20. New data shows that targeting MALT1 protease activity may be a promising therapeutic strategy for treating aggressive B cell lymphomas.
ncbi.nlm.nih.gov
